Mass Spectrometry-Based Proteomic Discovery of Prognostic Biomarkers in Adrenal Cortical Carcinoma

被引:22
|
作者
Jang, Han Na [1 ,2 ]
Moon, Sun Joon [1 ,3 ]
Jung, Kyeong Cheon [4 ,5 ,6 ]
Kim, Sang Wan [1 ,7 ]
Kim, Hyeyoon [8 ]
Han, Dohyun [8 ]
Kim, Jung Hee [1 ,2 ]
机构
[1] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul 03080, South Korea
[2] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 03080, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Internal Med, Div Endocrinol & Metab,Sch Med, Seoul 03080, South Korea
[4] Seoul Natl Univ, Dept Pathol, Coll Med, Seoul 03080, South Korea
[5] Seoul Natl Univ, Dept Translat Med, Coll Med, Seoul 03080, South Korea
[6] Seoul Natl Univ, Grad Sch, Integrated Major Innovat Med Sci, Seoul 03080, South Korea
[7] Seoul Natl Univ, Dept Internal Med, Seoul Metropolitan Govt, Boramae Med Ctr, Seoul 03080, South Korea
[8] Seoul Natl Univ Hosp, Biomed Res Inst, Prote Core Facil, Seoul 03080, South Korea
基金
新加坡国家研究基金会;
关键词
adrenal cortical carcinoma; prognosis; proteomics; mass spectrometry; HNRNPA1; ADRENOCORTICAL CARCINOMA; GENOMIC CHARACTERIZATION; COMPUTATIONAL PLATFORM; POOR-PROGNOSIS; EXPRESSION; PROTEIN; TUMORS; CLASSIFICATION; DISEASE; PREDICTORS;
D O I
10.3390/cancers13153890
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis and who require adjuvant therapy. We developed the prognostic biomarker candidates of ACC using mass-spectrometry-based proteomics and machine learning algorithm. We further validated them in The Cancer Genome Atlas data and performed the survival analysis according to the expression levels of each protein. In addition, HNRNPA1, the protein identified as a prognostic marker of ACC based on proteomics, was validated in the immunohistochemistry staining. The prognostic protein biomarkers of ACC found in this study are expected to help determine the appropriate treatment plan for patients. Adrenal cortical carcinoma (ACC) is an extremely rare disease with a variable prognosis. Current prognostic markers have limitations in identifying patients with a poor prognosis. Herein, we aimed to investigate the prognostic protein biomarkers of ACC using mass-spectrometry-based proteomics. We performed the liquid chromatography-tandem mass spectrometry (LC-MS/MS) using formalin-fixed paraffin-embedded (FFPE) tissues of 45 adrenal tumors. Then, we selected 117 differentially expressed proteins (DEPs) among tumors with different stages using the machine learning algorithm. Next, we conducted a survival analysis to assess whether the levels of DEPs were related to survival. Among 117 DEPs, HNRNPA1, C8A, CHMP6, LTBP4, SPR, NCEH1, MRPS23, POLDIP2, and WBSCR16 were significantly correlated with the survival of ACC. In age- and stage-adjusted Cox proportional hazard regression models, only HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 expression remained significant. These five proteins were also validated in TCGA data as the prognostic biomarkers. In this study, we found that HNRNPA1, LTBP4, MRPS23, POLDIP2, and WBSCR16 were protein biomarkers for predicting the prognosis of ACC.
引用
收藏
页数:20
相关论文
共 50 条
  • [21] Mass Spectrometry-Based Proteomics in Preclinical Drug Discovery
    Schirle, Markus
    Bantscheff, Marcus
    Kuster, Bernhard
    CHEMISTRY & BIOLOGY, 2012, 19 (01): : 72 - 84
  • [22] Biomarker discovery in mass spectrometry-based urinary proteomics
    Thomas, Samuel
    Hao, Ling
    Ricke, William A.
    Li, Lingjun
    PROTEOMICS CLINICAL APPLICATIONS, 2016, 10 (04) : 358 - 370
  • [23] Advances in mass spectrometry-based clinical biomarker discovery
    Crutchfield, Christopher A.
    Thomas, Stefani N.
    Sokoll, Lori J.
    Chan, Daniel W.
    CLINICAL PROTEOMICS, 2016, 13
  • [24] Mass Spectrometry-based Quantitative Analysis and Biomarker Discovery
    Suzuki, Naoto
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2011, 131 (09): : 1305 - 1309
  • [25] Mass Spectrometry-Based Proteomics in Molecular Diagnostics: Discovery of Cancer Biomarkers Using Tissue Culture
    Paul, Debasish
    Kumar, Avinash
    Gajbhiye, Akshada
    Santra, Manas K.
    Srikanth, Rapole
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [26] Advances in mass spectrometry-based clinical biomarker discovery
    Christopher A. Crutchfield
    Stefani N. Thomas
    Lori J. Sokoll
    Daniel W. Chan
    Clinical Proteomics, 2016, 13
  • [27] Proteome discovery pipeline for mass spectrometry-based proteomics
    Gough, Erik
    Oh, Cheolhwan
    He, Jing
    Riley, Catherine P.
    Buck, Charles R.
    Zhang, Xiang
    BMC BIOINFORMATICS, 2008, 9 (Suppl 7)
  • [28] Mass spectrometry-based antigen discovery for cancer immunotherapy
    Bassani-Sternberg, Michal
    Coukos, George
    CURRENT OPINION IN IMMUNOLOGY, 2016, 41 : 9 - 17
  • [29] Mass Spectrometry-based Hair Metabolomics for Biomarker Discovery
    Lee, Yu Ra
    Hong, Jongki
    Chung, Bong Chul
    MASS SPECTROMETRY LETTERS, 2022, 13 (01) : 2 - 10
  • [30] Mass Spectrometry-Based Salivary Proteomics for the Discovery of Head and Neck Squamous Cell Carcinoma
    Jarai, Tamas
    Maasz, Gabor
    Burian, Andras
    Bona, Agnes
    Jambor, Eva
    Gerlinger, Imre
    Mark, Laszlo
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (03) : 623 - 628